User Profile
Corporate
Careers
FAQ
Blog
Pricing
Social
General Modals
Advanced Modals
Search
Wizards
Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites R01 applications that investigate mitochondrial-nuclear communication in the context of neurobiology and Alzheimer's disease (AD) and AD-related dementias (AD/ADRD). This research will transform our understanding of how mitochondrially derived metabolites can impact nuclear gene expression and how changes to nuclear function can impact mitochondrial activity. This has the potential to serve as the foundation for the development of future AD/ADRD therapies that specifically target mitochondrial function as well as shed light on the role that mitochondria play in aging and neurodegeneration.
Deadlines:
- Letter of Intent: October 7, 2024
- Application: November 7, 2024
RFA-AG-25-026 Expiration Date November 08, 2024
Specialties
Eligibility Requirements
Sponsor Details
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Grant
Final Deadline:
Nov 07, 2024
Funding Amount:
Varies
Host Details
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.
Invite Gmail Contacts